KR101593242B1 - ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 - Google Patents
６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR101593242B1 KR101593242B1 KR1020107008968A KR20107008968A KR101593242B1 KR 101593242 B1 KR101593242 B1 KR 101593242B1 KR 1020107008968 A KR1020107008968 A KR 1020107008968A KR 20107008968 A KR20107008968 A KR 20107008968A KR 101593242 B1 KR101593242 B1 KR 101593242B1
- Authority
- KR
- South Korea
- Prior art keywords
- halo
- optionally substituted
- alkyl
- mmol
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VNBPTVUUYCWQRV-UHFFFAOYSA-N CC(C)(C)OC(NCc(cc1)cc2c1N=C(C)N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(NCc(cc1)cc2c1N=C(C)N(C(CCC(N1)=O)C1=O)C2=O)=O VNBPTVUUYCWQRV-UHFFFAOYSA-N 0.000 description 1
- LZQXGKFZKXVDQS-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(c(Cl)ccc2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(c(Cl)ccc2)c2C1=O LZQXGKFZKXVDQS-UHFFFAOYSA-N 0.000 description 1
- UIUCFYZAMIWOSY-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(Cl)c2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(Cl)c2)c2C1=O UIUCFYZAMIWOSY-UHFFFAOYSA-N 0.000 description 1
- MALNRQAZVXFDBU-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(F)c2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(ccc(F)c2)c2C1=O MALNRQAZVXFDBU-UHFFFAOYSA-N 0.000 description 1
- JVKCFSMUWKKVAM-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3ccc(C(F)(F)F)cc3)=O)cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3ccc(C(F)(F)F)cc3)=O)cc2C1=O JVKCFSMUWKKVAM-UHFFFAOYSA-N 0.000 description 1
- FMGRSJDHPQPYBI-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3cccc(C(F)(F)F)c3)=O)cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2ccc(CNC(c3cccc(C(F)(F)F)c3)=O)cc2C1=O FMGRSJDHPQPYBI-UHFFFAOYSA-N 0.000 description 1
- OZWMRWXITLBHIL-UHFFFAOYSA-N O=C(CCC1N(C=Nc(c2c3)ccc3Br)C2=O)NC1=O Chemical compound O=C(CCC1N(C=Nc(c2c3)ccc3Br)C2=O)NC1=O OZWMRWXITLBHIL-UHFFFAOYSA-N 0.000 description 1
- SHSGQQNSSYEXIJ-UHFFFAOYSA-N O=C(CCC1N(C=Nc(cc2)c3cc2Cl)C3=O)NC1=O Chemical compound O=C(CCC1N(C=Nc(cc2)c3cc2Cl)C3=O)NC1=O SHSGQQNSSYEXIJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99567607P | 2007-09-26 | 2007-09-26 | |
| US60/995,676 | 2007-09-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100080540A KR20100080540A (ko) | 2010-07-08 |
| KR101593242B1 true KR101593242B1 (ko) | 2016-02-11 |
Family
ID=40225265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008968A Expired - Fee Related KR101593242B1 (ko) | 2007-09-26 | 2008-09-25 | ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8492395B2 (enExample) |
| EP (1) | EP2200999B1 (enExample) |
| JP (1) | JP5637852B2 (enExample) |
| KR (1) | KR101593242B1 (enExample) |
| CN (2) | CN101952272B (enExample) |
| AU (1) | AU2008305581C1 (enExample) |
| BR (1) | BRPI0817525A2 (enExample) |
| CA (1) | CA2704710C (enExample) |
| CO (1) | CO6270228A2 (enExample) |
| CR (1) | CR11355A (enExample) |
| ES (1) | ES2523925T3 (enExample) |
| IL (2) | IL204763A (enExample) |
| MX (1) | MX347987B (enExample) |
| MY (1) | MY157495A (enExample) |
| NI (1) | NI201000041A (enExample) |
| NZ (1) | NZ584425A (enExample) |
| RU (1) | RU2476432C2 (enExample) |
| SG (2) | SG176442A1 (enExample) |
| UA (1) | UA102078C2 (enExample) |
| WO (1) | WO2009042177A1 (enExample) |
| ZA (1) | ZA201002303B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2066656E (pt) | 2006-09-26 | 2012-06-28 | Celgene Corp | Derivados de quinazolina substituídos em 5 como agentes antitumorais |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| NZ598462A (en) * | 2009-08-31 | 2012-12-21 | Merck Sharp & Dohme | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| PL2683384T3 (pl) * | 2011-03-11 | 2016-06-30 | Celgene Corp | Sposoby leczenia nowotworu z użyciem 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)piperydyno-2,6-dionu |
| CA3037184C (en) | 2011-03-11 | 2021-04-06 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| HK1221174A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法 |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| EP3925609B1 (en) | 2014-08-22 | 2025-07-30 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| BR112017028530A2 (pt) | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US11001566B2 (en) * | 2016-01-14 | 2021-05-11 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2018208123A1 (ko) * | 2017-05-12 | 2018-11-15 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN111885914B (zh) * | 2017-10-27 | 2022-05-13 | 投资健康有限责任公司 | 使用芴衍生物制造扩增的造血干细胞的组合物和方法 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| MX2021012524A (es) | 2019-04-12 | 2021-11-12 | C4 Therapeutics Inc | Degradadores triciclicos de ikaros y aiolos. |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| US20230303539A1 (en) * | 2020-08-14 | 2023-09-28 | Shanghaitech University | Immunoregulatory compound and antitumor application thereof |
| WO2023287726A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of cancer using botulinum toxin and nitrous oxide |
| CN119325475A (zh) | 2022-06-06 | 2025-01-17 | C4医药公司 | 双环取代的戊二酰亚胺cereblon结合剂 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| ES2198546T3 (es) * | 1996-05-15 | 2004-02-01 | Pfizer Inc. | 4(3h)-quinazolinonas 2,3,6 trisustituidas. |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| WO2003041326A2 (en) | 2001-11-09 | 2003-05-15 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| US7381730B2 (en) * | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1537089A4 (en) * | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | CONNECTIONS, COMPOSITIONS AND PROCEDURES |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20050143420A1 (en) | 2003-12-02 | 2005-06-30 | Moutouh-De Parseval Laure | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| CA2560221C (en) | 2004-03-22 | 2010-12-07 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| MXPA06011236A (es) * | 2004-04-02 | 2007-01-16 | Prana Biotechnology Ltd | Compuestos neurologicamente activos. |
| ZA200609226B (en) | 2004-04-23 | 2008-06-25 | Celgene Corp | Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of pulmonary hypertension |
| KR20070028536A (ko) * | 2004-06-15 | 2007-03-12 | 아스트라제네카 아베 | 항암제로서의 치환된 퀴나졸론 |
| AU2005304420A1 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
| WO2006060507A2 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| ES2434946T3 (es) | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
| DK1928492T3 (da) | 2005-09-01 | 2011-06-06 | Celgene Corp | Immunologiske anvendelser af immunmodulatoriske forbindelser til vaccine og terapi mod infektionssygdomme |
| PT2066656E (pt) * | 2006-09-26 | 2012-06-28 | Celgene Corp | Derivados de quinazolina substituídos em 5 como agentes antitumorais |
-
2008
- 2008-09-25 CA CA2704710A patent/CA2704710C/en not_active Expired - Fee Related
- 2008-09-25 RU RU2010116273/04A patent/RU2476432C2/ru not_active IP Right Cessation
- 2008-09-25 MY MYPI2010001343A patent/MY157495A/en unknown
- 2008-09-25 KR KR1020107008968A patent/KR101593242B1/ko not_active Expired - Fee Related
- 2008-09-25 UA UAA201004853A patent/UA102078C2/ru unknown
- 2008-09-25 CN CN200880117819.9A patent/CN101952272B/zh not_active Expired - Fee Related
- 2008-09-25 SG SG2011080553A patent/SG176442A1/en unknown
- 2008-09-25 SG SG10201503486XA patent/SG10201503486XA/en unknown
- 2008-09-25 NZ NZ584425A patent/NZ584425A/en not_active IP Right Cessation
- 2008-09-25 WO PCT/US2008/011124 patent/WO2009042177A1/en not_active Ceased
- 2008-09-25 US US12/238,354 patent/US8492395B2/en active Active
- 2008-09-25 JP JP2010526944A patent/JP5637852B2/ja active Active
- 2008-09-25 CN CN201410362879.4A patent/CN104211684A/zh active Pending
- 2008-09-25 ES ES08834539.2T patent/ES2523925T3/es active Active
- 2008-09-25 EP EP08834539.2A patent/EP2200999B1/en active Active
- 2008-09-25 MX MX2010003355A patent/MX347987B/es active IP Right Grant
- 2008-09-25 BR BRPI0817525-0A2A patent/BRPI0817525A2/pt not_active Application Discontinuation
- 2008-09-25 AU AU2008305581A patent/AU2008305581C1/en not_active Ceased
-
2010
- 2010-03-25 NI NI201000041A patent/NI201000041A/es unknown
- 2010-03-25 IL IL204763A patent/IL204763A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02303A patent/ZA201002303B/en unknown
- 2010-04-07 CR CR11355A patent/CR11355A/es unknown
- 2010-04-20 CO CO10046034A patent/CO6270228A2/es not_active Application Discontinuation
-
2013
- 2013-06-11 IL IL226870A patent/IL226870A/en active IP Right Grant
- 2013-06-26 US US13/928,147 patent/US9096573B2/en active Active
-
2015
- 2015-06-24 US US14/749,448 patent/US9586929B2/en active Active
-
2017
- 2017-01-25 US US15/415,332 patent/US9834538B2/en active Active
- 2017-11-07 US US15/806,254 patent/US20180118713A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| Acta Pharm.Suecica. vol.9, pp.431-446 (1972.) |
| Organic Chemistry and Pharmacology Departments Faculty of Pharmacy. Cairo, pp.273-284 (1976.) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101593242B1 (ko) | ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 | |
| RU2617989C2 (ru) | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения | |
| RU2448101C2 (ru) | 5-замещенные изоиндолиновые соединения | |
| RU2471794C2 (ru) | 4'-о-замещенные изоиндолиновые производные и содержащие их композиции и способы их применения | |
| JP2011522803A (ja) | ５−置換イソインドリン化合物 | |
| HK1139934B (en) | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| J201 | Request for trial against refusal decision | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20190203 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20190203 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |